Skip to Content

Epoprostenol Disease Interactions

There are 2 disease interactions with epoprostenol:


Epoprostenol (applies to epoprostenol) CHF

Major Potential Hazard, High plausibility. Applicable conditions: Congestive Heart Failure

The use of epoprostenol is contraindicated in patients with heart failure due to reduced severe left ventricular systolic dysfunction. A large study involving such patients was terminated after an interim analysis revealed a higher mortality in the group receiving epoprostenol plus standard therapy than in the group receiving standard therapy alone.


  1. Pickles H, O'Grady J "Side effects occurring during administration of epoprostenol (prostacyclin, PGI2), in man." Br J Clin Pharmacol 14 (1982): 177-85
  2. "Product Information. Flolan (epoprostenol)." Glaxo Wellcome, Research Triangle Park, NC.
  3. "Epoprostenol for primary pulmonary hypertension." Med Lett Drugs Ther 38 (1996): 14-5
  4. Bugiardini R, Galvani M, Ferrini D, Gridelli C, Tollemeto D, Macri N, Puddu P, Lenzi S "Myocardial ischemia during intravenous prostacyclin administration: hemodynamic findings and precautionary measures." Am Heart J 113 (1987): 234-40
  5. Bugiardini R, Galvani M, Ferrini D, Gridelli C, Tollemeto D, Mari L, Puddu P, Lenzi S "Myocardial ischemia induced by prostacyclin and iloprost." Clin Pharmacol Ther 38 (1985): 101-8
View all 5 references

Epoprostenol (applies to epoprostenol) bleeding

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cerebral Thrombosis/Embolism

Epoprostenol is a potent inhibitor of platelet aggregation. Therefore, expect an increased risk for hemorrhagic complications, particularly for patients with other risk factors for bleeding. Caution and close monitoring is advised.

Epoprostenol drug interactions

There are 285 drug interactions with epoprostenol

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.